tiprankstipranks
Advertisement
Advertisement
Theravance Biopharma options imply 3.2% move in share price post-earnings
PremiumThe FlyTheravance Biopharma options imply 3.2% move in share price post-earnings
1M ago
Theravance Biopharma downgraded to Perform from Outperform at Oppenheimer
Premium
The Fly
Theravance Biopharma downgraded to Perform from Outperform at Oppenheimer
1M ago
Theravance Biopharma downgraded at Oppenheimer after ampreloxetine miss
Premium
The Fly
Theravance Biopharma downgraded at Oppenheimer after ampreloxetine miss
1M ago
Theravance Biopharma falls 28% to $13.55 in pre-market trading
PremiumThe FlyTheravance Biopharma falls 28% to $13.55 in pre-market trading
1M ago
Theravance Biopharma implements cost reduction actions after study results
Premium
The Fly
Theravance Biopharma implements cost reduction actions after study results
1M ago
Theravance Biopharma Restructures After Ampreloxetine Trial Failure
Premium
Company Announcements
Theravance Biopharma Restructures After Ampreloxetine Trial Failure
1M ago
Largest borrow rate increases among liquid names
PremiumThe FlyLargest borrow rate increases among liquid names
2M ago
Theravance Biopharma price target raised to $27 from $20 at H.C. Wainwright
Premium
The Fly
Theravance Biopharma price target raised to $27 from $20 at H.C. Wainwright
2M ago
TBPH Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
TBPH Earnings this Week: How Will it Perform?
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100